https://allsci.com/news/venture-financing/ai-disease-models-patient-data-network-bio/ AllScien 2026-08-19T15:19:13.007481Z Network Bio raises USD 50m for patient tissue-trained AI platform https://allsci.com/news/licensing-and-partnerships/klotho-ind-filing-jocasta-eliminates-ip-risk/ AllScien 2026-08-19T15:16:40.815903Z Jocasta cuts Unity from α-klotho IP chain with direct UCSF deal https://allsci.com/news/first-in-human-trials/crispr-treg-therapy-cancer-coregens-crispr-edited/ AllScien 2026-08-19T15:03:37.633033Z CoRegen takes CRISPR-edited Tregs into first human cancer trial https://allsci.com/news/venture-financing/oncolytic-immunotherapy-funding-kalivir-raises/ AllScien 2026-08-19T14:58:39.701241Z KaliVir raises USD 14m as oncolytic virus clears first IV cohort https://allsci.com/news/licensing-and-partnerships/il-7-therapy-clinical-development-tolerance-bio/ AllScien 2026-08-19T14:17:46.800790Z Tolerance Bio licenses clinical-stage IL-7 therapy to enter thymic function studies https://allsci.com/news/clinical-trials/enhertu-her2-lung-cancer-becomes-first/ AllScien 2026-08-19T13:55:10.390198Z Enhertu becomes first HER2-directed therapy to beat chemoimmunotherapy in 1st-line lung cancer https://allsci.com/news/clinical-trials/regn7041-uveitis-trial-regeneron-terminates-phase/ AllScien 2026-08-19T13:49:30.328923Z Regeneron halts first-in-human REGN7041 trial after safety event https://allsci.com/news/clinical-trials/prmt5-inhibitor-pancreatic-cancer-ideaya-partners/ AllScien 2026-08-19T13:19:41.676716Z Genentech doubles down on IDEAYA’s PRMT5 strategy with KRAS G12D combo https://allsci.com/news/licensing-and-partnerships/bioarctic-glioblastoma-collaboration-expands/ AllScien 2026-08-19T13:09:56.473165Z BioArctic expands BrainTransporter platform from neurodegeneration to glioblastoma with Mesenkia collaboration https://allsci.com/news/clinical-trials/pfizer-iga-nephropathy-trial-termination/ AllScien 2026-08-19T12:44:32.996437Z Pfizer drops IgAN candidate PF-07985631 over benefit-risk assessment https://allsci.com/news/clinical-trials/evogliptin-aortic-stenosis-trial-rednvia/ AllScien 2026-08-19T12:29:18.867558Z REDNVIA terminates Phase II/III trial of DPP-4 inhibitor evogliptin in aortic stenosis https://allsci.com/news/clinical-trials/neoantigen-therapy-melanoma-merck-and-modernas/ AllScien 2026-08-19T12:08:14.955167Z Merck, Moderna neoantigen therapy delivers landmark Phase III melanoma win https://allsci.com/news/research/senolytic-drug-mycobacterial-infection-senescent/ AllScien 2026-08-19T12:04:38.302544Z University of Milan team turns senolytic drug against hard-to-treat mycobacterial infection https://allsci.com/news/grants/type-1-diabetes-biomarkers-battelle-pacific/ AllScien 2026-08-19T08:51:11.081574Z NIH funds new blood biomarkers to track islet dysfunction in type 1 diabetes https://allsci.com/news/grants/oral-influenza-antiviral-stanford-secures-127m/ AllScien 2026-08-19T08:45:28.426804Z Stanford moving novel oral influenza antiviral toward IND with NIAID backing https://allsci.com/news/licensing-and-partnerships/eli-lilly-alzheimers-gsm-completes-usd-10-million/ AllScien 2026-08-19T08:41:59.751117Z Lilly completes USD 10m payment for preclinical Alzheimer's GSM from AlzeCure https://allsci.com/news/regulatory/pelareorep-colorectal-cancer-fda-aligns-with/ AllScien 2026-08-19T08:38:40.670386Z Oncolytics gains FDA alignment on pivotal path for pelareorep in colorectal cancer https://allsci.com/news/regulatory/parg-inhibitor-breast-cancer-858-therapeutics/ AllScien 2026-08-19T08:34:45.703514Z 858 Therapeutics' PARG inhibitor gets second fast-track award for breast cancer https://allsci.com/news/policy/fda-generative-ai-medical-devices-seeks-public/ AllScien 2026-08-19T08:32:33.861243Z FDA seeks input on regulatory framework for generative AI-enabled medical devices https://allsci.com/news/funding/avexitide-funding-phase-iii-amylyx-raises-usd/ AllScien 2026-08-19T08:28:49.525119Z Amylyx moves to raise USD 350m after avexitide's Phase III hypoglycemia win https://allsci.com/news/licensing-and-partnerships/gsk-dengue-antibody-license-secures-exclusive/ AllScien 2026-08-19T08:13:42.286884Z GSK secures preclinical dengue antibody from Chugai https://allsci.com/news/development/biomarin-alesta-acquisition-hypophosphatasia/ AllScien 2026-08-18T17:19:00.312056Z BioMarin pays USD 275m upfront for early-stage oral HPP bet ALE1 https://allsci.com/news/grants/alzheimers-prevention-down-syndrome-brigham-and/ AllScien 2026-08-18T17:13:40.927362Z Brigham wins NIA funding to test lamivudine against retrotransposons in Down syndrome Alzheimer's https://allsci.com/news/research/virtual-cell-simulation-genbio-ai-releases-aido/ AllScien 2026-08-18T16:52:56.695334Z GenBio AI unveils multiscale virtual cell model spanning DNA to phenotype https://allsci.com/news/clinical-trials/exercise-mimicking-obesity-pill-envedas-shows/ AllScien 2026-08-18T15:59:33.353125Z Enveda clears Phase I with exercise-inspired pill targeting post-GLP-1 weight regain https://allsci.com/news/funding/neurothera-labs-funding-scisparc-funds-spinoff/ AllScien 2026-08-18T15:55:11.768406Z SciSparc funds NeuroThera Labs spinoff with CAD 5.4m financing round https://allsci.com/news/venture-financing/abcuro-series-d-funding-raises-usd-66m-to-advance/ AllScien 2026-08-18T15:53:37.627889Z Abcuro raises USD 66m to retest ulviprubart after Phase II/III IBM miss https://allsci.com/news/grants/aml-treatment-resistance-research-dana-farber/ AllScien 2026-08-18T15:47:09.405058Z Dana-Farber wins NCI leukemia SPORE to tackle resistance across emerging AML drug classes https://allsci.com/news/regulatory/fda-fast-track-endometrial-cancer-grants/ AllScien 2026-08-18T14:27:26.355309Z Faeth's PIKTOR combo gets FDA fast track for biomarker-selected endometrial cancer https://allsci.com/news/clinical-trials/novo-nordisk-obesity-trial-registers-phase-with/ AllScien 2026-08-18T14:20:56.033813Z Novo Nordisk takes mystery obesity drug into FIH trial against semaglutide https://allsci.com/news/research/bacillus-cereus-immunotherapy-hepatocellular-carcinoma/ AllScien 2026-08-18T13:55:00.020362Z Nanjing Medical University researchers link bacterial enzyme to improved liver cancer immunotherapy https://allsci.com/news/pharma/dersimelagon-acquisition-leo-pharma-acquires-for/ AllScien 2026-08-18T12:26:24.981307Z LEO Pharma picks up dersimelagon for USD 435m to challenge Scenesse in rare photodermatoses https://allsci.com/news/ipo-public-listing/ingenia-therapeutics-kosdaq-listing-lists-on-to/ AllScien 2026-08-18T12:20:27.160834Z Ingenia Therapeutics lists on KOSDAQ to fund vascular antibody pipeline https://allsci.com/news/clinical-trials/avexitide-hypoglycemia-phase-iii-amylyxs-cuts/ AllScien 2026-08-18T12:16:46.921291Z Amylyx's avexitide cuts hypoglycemic events by 55% in Phase III post-bariatric trial https://allsci.com/news/first-in-human-trials/atx-898-clinical-trial-antares-launches/ AllScien 2026-08-18T10:48:34.407075Z Antares launches FIH trial of ATX-898 with CDK4/6 breast cancer combos https://allsci.com/news/first-in-human-trials/mek-inhibitor-wet-amd-trial-filamon-launches/ AllScien 2026-08-18T10:24:46.702003Z Filamon launches first-in-human trial of topical MEK inhibitor in wet AMD